1. Market Research
  2. > Inviragen, Inc. - Product Pipeline Review - 2013

Inviragen, Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 26 pages

Inviragen, Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Inviragen, Inc. - Product Pipeline Review - 2013” provides data on the Inviragen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Inviragen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Inviragen, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Inviragen, Inc. - Brief Inviragen, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Inviragen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Inviragen, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Inviragen, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Inviragen, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Inviragen, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Inviragen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Inviragen, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Inviragen, Inc. and identify potential opportunities in those areas.

Table Of Contents

Inviragen, Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Inviragen, Inc. Snapshot 4
Inviragen, Inc. Overview 4
Key Information 4
Key Facts 4
Inviragen, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Inviragen, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Inviragen, Inc. - Pipeline Products Glance 9
Inviragen, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Inviragen, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Inviragen, Inc. - Drug Profiles 12
Avian Influenza Vaccine 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Chikungunya Vaccine 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
DENVax 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
HPV Vaccine 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
INV-21 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Japanese Encephalitis Vaccine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Plague Vaccine 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Inviragen, Inc. - Pipeline Analysis 19
Inviragen, Inc. - Pipeline Products by Therapeutic Class 19
Inviragen, Inc. - Pipeline Products by Route of Administration 20
Inviragen, Inc. - Recent Pipeline Updates 21
Inviragen, Inc. - Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26

List of Tables

Inviragen, Inc., Key Information 4
Inviragen, Inc., Key Facts 4
Inviragen, Inc. - Pipeline by Indication, 2013 6
Inviragen, Inc. - Pipeline by Stage of Development, 2013 7
Inviragen, Inc. - Monotherapy Products in Pipeline, 2013 8
Inviragen, Inc. - Phase II, 2013 9
Inviragen, Inc. - Phase I, 2013 10
Inviragen, Inc. - Preclinical, 2013 11
Inviragen, Inc. - Pipeline By Therapeutic Class, 2013 19
Inviragen, Inc. - Pipeline By Route of Administration, 2013 20
Inviragen, Inc. - Recent Pipeline Updates, 2013 21
Inviragen, Inc., Other Locations 24

List of Figures

Inviragen, Inc. - Pipeline by Indication, 2013 6
Inviragen, Inc. - Pipeline by Stage of Development, 2013 7
Inviragen, Inc. - Monotherapy Products in Pipeline, 2013 8
Inviragen, Inc. - Pipeline By Therapeutic Class, 2013 19
Inviragen, Inc. - Pipeline By Route of Administration, 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.